

Author Relationships With Industry and Other Entities (Comprehensive)—2020 ACC/AHA Clinical Performance and Quality Measures for Heart Failure (August 2020)

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Paul A. Heidenreich <i>(Chair)</i>	Stanford VA Palo Alto Health Care System—Professor of Medicine	None	None	None	None	<ul style="list-style-type: none"> • HFSA • ICER • Joint Commission 	None
Gregg C. Fonarow <i>(Vice Chair)</i>	UCLA Medical Center—Professor of Medicine	<ul style="list-style-type: none"> • Abbott* • Amgen • AstraZeneca • CHF Solutions • Edwards Lifesciences* • Janssen Pharmaceuticals • Medtronic • Merck • Novartis* • Regeneron 	None	None	<ul style="list-style-type: none"> • Medtronic • NHLBI* • NIH/NIAID* • Novartis* 	<ul style="list-style-type: none"> • ACC/AHA TFPMT • ACC ACTION Registry GWTG Steering Committee Chair† • AHA Consumer Health Quality Coordinating Committee† • Boston Scientific • JAMA Cardiology* • Steering Committee GWTG† 	None
Khadijah Breathett‡	UA College of Medicine, Tucson—Assistant Professor of Medicine	None	None	None	<ul style="list-style-type: none"> • AHA • NIH* • UA* • Women As One* 	None	None
Corrine Y. Jurgens	Boston College, School of Nursing—Associate Professor	None	None	None	None	<ul style="list-style-type: none"> • HFSA† 	None
Barbara A. Pisani	Wake Forest Baptist Medical Center, Heart Transplant and Mechanical Circulatory Support—Medical	None	None	None	None	<ul style="list-style-type: none"> • Abbott† • Amgen§ 	None

Author Relationships With Industry and Other Entities (Comprehensive)—2020 ACC/AHA Clinical Performance and Quality Measures for Heart Failure (August 2020)

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
	Director, Heart Failure					<ul style="list-style-type: none"> • Amgen— GALACTIC-HF Trial (PI) • Medtronic† • Novartis— PIONEER Trial (PI) • Sanofi- Aventis— SOLOIST Study (PI) • Zoll—BMAD Study (PI) 	
Bunny J. Pozehl	University of Nebraska Medical Center, Omaha Division—Professor College of Nursing	None	None	None	None	<ul style="list-style-type: none"> • Abbott • Relypsa 	None
Kevin Shah	University of Utah, Salt Lake City— Advanced Heart Failure & Transplant Cardiology Fellow	None	None	None	None	<ul style="list-style-type: none"> • Medtronic 	None
John A. Spertus	Saint Luke’s Mid America Heart Institute—Director, Health Outcomes Research; University of Missouri-Kansas City—Professor	<ul style="list-style-type: none"> • Amgen • AstraZeneca* • Bayer • Boehringer Ingelheim* • Janssen Pharmaceuticals* • Merck* • Novartis* • Regeneron Pharmaceuticals* • SAQ, KCCQ, and PAQ* • United Healthcare 	None	<ul style="list-style-type: none"> • Health Outcomes Sciences* 	<ul style="list-style-type: none"> • ACCF* 	<ul style="list-style-type: none"> • Abbott • ACC† • AHA† • AstraZeneca UK Limited • Blue Cross Blue Shield of Kansas City* • Outcomes Instruments† • Medtronic • Novartis* 	None

Author Relationships With Industry and Other Entities (Comprehensive)—2020 ACC/AHA Clinical Performance and Quality Measures for Heart Failure (August 2020)

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Kenneth G. Taylor¶	Piedmont Heart Institute—General and Interventional Cardiologist	None	None	None	None	<ul style="list-style-type: none"> • Abbott§ • Biotronic§ • Cor§ • Diem Bioventures† • Duke Clinical Research Institute§ • HFSA† • Medtronic§ • Novartis§ • OrbusNeich§ • Siemens§ • Thoratec§ 	<ul style="list-style-type: none"> • Defendant, Professional opinion on cause of death case, not expert witness, 2018
Jennifer T. Thibodeau	University of Texas Southwestern Medical Center—Associate Professor; Director, Heart Failure; Interim Section Chief, Heart Failure, Cardiac Transplantation, Ventricular Assist Devices	None	None	None	<ul style="list-style-type: none"> • Novartis 	<ul style="list-style-type: none"> • AHA§ • Amgen§ • AstraZeneca§ • CareDx§ • Cytogenics Inc. § • Eidos Therapeutics§ • NIH—Dilated Cardiomyopathy Study (Co-PI) • Novartis§ • St. Luke’s Hospital§ 	None
Clyde W. Yancy#	Northwestern University, Feinberg School of Medicine—Magerstadt Professor of Medicine; Division of Cardiology—Chief	None	None	None	None	<ul style="list-style-type: none"> • Abbott† • JAMA <i>Cardiology</i>* • Department of Health and 	None

Author Relationships With Industry and Other Entities (Comprehensive)—2020 ACC/AHA Clinical Performance and Quality Measures for Heart Failure (August 2020)

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
						Human Services	
Boback Ziaeian	UCLA David Geffen School of Medicine—Assistant Professor; VA Greater Los Angeles Healthcare System—Director of Telecardiology	• AHA	None	None	<ul style="list-style-type: none"> • ACC • AHA* • NIH* 	None	None

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥\$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

*Significant relationship.

†No financial benefit.

‡CMS reported payments to Dr. Breathett in 2019 related to food, beverage, travel, and lodging for Abbott; however, she disagrees with this report. Dr. Breathett was not the lead author on any measures.

§This disclosure was entered under the Clinical Trial Enroller category in the ACC’s disclosure system. To appear in this category, the author acknowledges that there is no direct or institutional relationship with the trial sponsor as defined in the (ACCF or ACC/AHA) Disclosure Policy for Writing Committees.

|| The CMS Open Payments website reported payments to Dr. Shah in 2018 related to food and beverage as well as travel and lodging payments from Medtronic. Dr. Shah confirmed that the payments were correct. When the payments were reviewed using specific ACC/AHA criteria, they were considered to represent a relevant relationship with industry. Given the current policy that at least 51% of the writing committee must be free of relevant RWI, the decision was made to remove Dr. Shah from the writing committee. The only measure that was drafted by Dr. Shah was previously removed from the measure set and he did not participate in any further discussions and review of manuscript.

¶CMS reported a food and beverage payment from Novartis to Dr. Taylor in 2019, however, he disagrees with this report. Novartis has marked the food and beverage entry for deletion. Dr. Taylor was not the lead author on any measures.

#CMS reported a food and beverage payment from Edwards Lifesciences to Dr. Yancy in 2019, however, he disagrees with this report. Edwards Lifesciences was deemed to be a non-relevant company with regards to the performance measures.

ACC indicates American College of Cardiology; ACCF, American College of Cardiology Foundation; ACTION, Acute Coronary Treatment and Intervention Outcomes Network; AHA, American Heart Association; GWTG, Get With The Guidelines; HF, heart failure; HFSA, Heart Failure Society of America; ICER, Institute for Clinical Economic Review; *JAMA*, *Journal of the American Medical Association*; KCCQ, Kansas City Cardiomyopathy Questionnaire; NHLBI, National Heart, Lung, and Blood Institute; NIAID, National Institute of Allergy and Infectious Diseases; NIH, National Institutes of Health; PAQ, Peripheral Artery Questionnaire; PI, principal investigator; SAQ, Seattle Angina Questionnaire; TFPM,

Author Relationships With Industry and Other Entities (Comprehensive)—2020 ACC/AHA Clinical Performance and Quality Measures for Heart Failure (August 2020)

Task Force on Performance Measures; UA, University of Arizona; UCLA, University of California, Los Angeles; UK, United Kingdom; UT, University of Texas; and VA, Veterans Affairs.